Overview of chemotherapy-induced diarrhea.
OBJECTIVE
To provide a general overview of chemotherapy-induced diarrhea (CID) that will highlight the pathophysiology, incidence, and impact of this problem, as well as describe the oncology nurse's role in the management of CID.


METHODS
Primary and tertiary literature, the authors' clinical experience.


CONCLUSIONS
CID is a frequent complication of many types of chemotherapy that can significantly affect patient quality of life, increase treatment costs, and limit the ability to deliver full doses of chemotherapy. Because patients may be reluctant to discuss diarrhea with their health care providers, vigilance on the part of the health care team is needed.


CONCLUSIONS
Through ongoing, regular patient contact, the oncology nurse is uniquely situated to monitor patients for the development of CID, assess its severity, and provide guidance to the health care team on the patient's status.
Viele
Carol S
CS
Department of Nursing, University of California at San Francisco, 505 Parnassus Dr, San Francisco, CA 94143, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000139:chemically induced* / Q000451:nursing* / Q000517:prevention & control; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing*; D009723:Nurse-Patient Relations; D009730:Nursing Assessment; D015404:Nursing Methodology Research; D015282:Octreotide / Q000009:adverse effects; D009859:Oncology Nursing / Q000592:standards*; D011788:Quality of Life
D000077146:Irinotecan; D015282:Octreotide; D005472:Fluorouracil; D002166:Camptothecin